{"ticker": {"uuid": "e4dcdb7c-2815-4175-be6f-1d899e923957", "symbol": "MIRA", "name": "MIRA Pharmaceuticals, Inc. Common Stock", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Drug Manufacturers - General"}, "articles": [{"title": "MIRA Pharmaceuticals (NASDAQ: MIRA) reports encouraging preclinical data for non-opioid pain candidate MIRA-55", "summary": "MIRA Pharmaceuticals announced positive preclinical results for MIRA-55, its non-opioid drug candidate for chronic inflammatory pain. The company selected an optimized oral formulation that showed favorable oral bioavailability, sustained systemic exposure, and reproducible distr", "url": "https://www.stocktitan.net/sec-filings/MIRA/8-k-mira-pharmaceuticals-inc-reports-material-event-bfdc4b7a0fdb.html", "source_name": "Stock Titan", "published_at": "2026-07-10T12:09:40", "published_display": "10 Jul 2026 12:09", "sentiment": "positive", "sentiment_pct": 70, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mira Pharmaceuticals Says SKNY-1 in Obesity, Addiction Shows 'Favorable' Bioavailability in Preclinical Studies", "summary": "Mira Pharmaceuticals (NASDAQ:MIRA) announced that its obesity and addiction drug candidate, SKNY-1, demonstrated favorable bioavailability and brain penetration in preclinical pharmacokinetic studies. These results support the drug's potential for once-daily oral dosing and its a", "url": "https://www.moomoo.com/news/post/72527367/mira-pharmaceuticals-says-skny-1-in-obesity-addiction-shows-favorable?futusource=news_newspage_recommend", "source_name": "Moomoo", "published_at": "2026-07-07T02:10:58", "published_display": "07 Jul 2026 02:10", "sentiment": "positive", "sentiment_pct": 74, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MIRA's obesity-and-addiction drug shows brain and liver exposure", "summary": "MIRA Pharmaceuticals (NASDAQ:MIRA) reported positive preclinical results for SKNY-1, an oral drug candidate for obesity and addiction. The optimized formulation demonstrated favorable oral bioavailability, reproducible systemic exposure, robust brain penetration, and substantial ", "url": "https://www.stocktitan.net/news/MIRA/mira-pharmaceuticals-reports-successful-formulation-results-for-skny-04tgs9z4po05.html", "source_name": "Stock Titan", "published_at": "2026-07-06T13:10:09", "published_display": "06 Jul 2026 13:10", "sentiment": "positive", "sentiment_pct": 93, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Japan firm's plant-based soup stock helps meet halal, vegan demand", "summary": "", "url": "https://news.google.com/rss/articles/CBMiygFBVV95cUxOY1M0RktyOUp6bnF4NmQxdEw3dkpYajV1c1RweG5DLXJWck9ZTUV1MGRNWXl3X2tFbHZsRG5xLXdoTUtZdnUwNVp3cWxLTXBCOWd4UHJSbGlhdkZjcFNZR3l0ZnFwSnFySHY0bWFrcnV1NkdBOXE1TzVxTk84cjNwZHJhcWk4WkZ0UVdkaERxbGxWZlluejE3cnVUaXRzdmY0b2NXaEhjZ19yaVMyM3RBclN1V1JSR19oMFpsYmVBb05ndlBGNHpNWC13?oc=5", "source_name": "The Star", "published_at": "2026-07-05T07:00:00+00:00", "published_display": "05 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "macro", "event_label": "Macro sensitivity", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MIRA Q3 2025 Earnings: Narrower Loss Reported, Stock Declines - EBITDA Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxQQWVKaWxBRXNabFRVWnNEZFFaNEhXZFNRaGI3M3JlLTV2Sk1EWHpuUE9FYWtiaUg3R2xGMmtQTWZST3duTG0yYk05Z3pZSHRIaFU4amgySXpteW1RdUdYcDBkVDlRNDZ3OUhYTC1OUDBQTjlQdUM4UTJlWmdZOG9xdGEzTnBKTEcyS1JxT0tCenFsNDY5bXdBVldLUEhFUmM2S2JHd1FZaXdjUQ?oc=5", "source_name": "Donan\u0131mHaber", "published_at": "2026-07-02T07:00:00+00:00", "published_display": "02 Jul 2026 07:00", "sentiment": "negative", "sentiment_pct": 18, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MIRA Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Whalen Matthew Pratt", "summary": "This document is a statement of changes in beneficial ownership of securities for Director Whalen Matthew Pratt at MIRA Pharmaceuticals. It is filed as a Form 4, indicating a mandatory disclosure for insiders regarding transactions in the company's stock.", "url": "https://www.moomoo.com/news/notice/307531901/mira-pharmaceuticals-4-statement-of-changes-in-beneficial-ownership-of", "source_name": "Moomoo", "published_at": "2026-06-30T16:41:12", "published_display": "30 Jun 2026 16:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MIRA Pharmaceuticals, Inc.(NasdaqCM: MIRA) added to Russell 3000E Growth Benchmark", "summary": "MIRA Pharmaceuticals, Inc. (NasdaqCM: MIRA) has been added to the Russell 3000E Growth Benchmark. This addition highlights the company's growth trajectory and its increasing recognition within the financial markets. MIRA Pharmaceuticals is a clinical-stage company focused on deve", "url": "https://www.marketscreener.com/news/mira-pharmaceuticals-inc-nasdaqcm-mira-added-to-russell-3000e-growth-benchmark-ce7f5fdedf8af223", "source_name": "www.marketscreener.com", "published_at": "2026-06-30T04:38:58", "published_display": "30 Jun 2026 04:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MIRA Pharmaceuticals, Inc.(NasdaqCM:MIRA) added to Russell Microcap Growth Benchmark Index", "summary": "MIRA Pharmaceuticals, Inc. (NasdaqCM:MIRA) has been added to the Russell Microcap Growth Benchmark Index. The company is a clinical-stage pharmaceutical firm focused on developing therapeutics for neurological, neuropsychiatric, and metabolic disorders. Its pipeline includes oral", "url": "https://www.marketscreener.com/news/mira-pharmaceuticals-inc-nasdaqcm-mira-added-to-russell-microcap-growth-benchmark-index-ce7f5fded08df720", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T12:12:16", "published_display": "29 Jun 2026 12:12", "sentiment": "positive", "sentiment_pct": 95, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MIRA Pharmaceuticals, Inc.(NasdaqCM: MIRA) added to Russell 3000E Index", "summary": "MIRA Pharmaceuticals (NasdaqCM: MIRA), a clinical-stage pharmaceutical company, has been added to the Russell 3000E Index. The company focuses on developing therapeutics for neurologic, neuropsychiatric, and metabolic disorders, with a pipeline that includes drug candidates for n", "url": "https://www.marketscreener.com/news/mira-pharmaceuticals-inc-nasdaqcm-mira-added-to-russell-3000e-index-ce7f5fdcdd89fe25", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T03:09:57", "published_display": "29 Jun 2026 03:09", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of MIRA Pharmaceuticals, Inc. \u2013 NASDAQ:MIRA", "summary": "This article provides financial information for MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA), specifically focusing on its forward price-to-sales ratio. It appears to be a stub or a section from a larger financial data platform, indicating the company's status on the Nasdaq Stock Ma", "url": "https://www.tradingview.com/symbols/NASDAQ-MIRA/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T04:38:58", "published_display": "28 Jun 2026 04:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of MIRA Pharmaceuticals, Inc. \u2013 NASDAQ:MIRA", "summary": "This article provides financial information for MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) focusing on its price-to-earnings forward metric. It details the company's presence on the Nasdaq Stock Market and references data from ICE Data Services, FactSet, and Quartr for financial r", "url": "https://www.tradingview.com/symbols/NASDAQ-MIRA/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T04:08:53", "published_display": "27 Jun 2026 04:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MIRA Pharmaceuticals, Inc. Actuals & Estimates (FWB:K6S)", "summary": "This article provides an overview of MIRA Pharmaceuticals, Inc. (FWB:K6S), including financial actuals and estimates, stock forecasts, and company information. According to analysts, the stock has a maximum estimate of 8.18 EUR and a minimum estimate of 8.18 EUR, with the next ea", "url": "https://www.tradingview.com/symbols/FWB-K6S/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-27T02:40:21", "published_display": "27 Jun 2026 02:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MIRA Pharmaceuticals, Inc. Actuals & Estimates (MUN:K6S)", "summary": "This article provides an overview of MIRA Pharmaceuticals, Inc. (K6S) stock performance and financial data on the Munich Stock Exchange. It includes analyst forecasts, historical price data, upcoming earnings report dates, and key financial figures such as net income and employee", "url": "https://www.tradingview.com/symbols/MUN-K6S/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-27T01:39:32", "published_display": "27 Jun 2026 01:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of MIRA Pharmaceuticals, Inc. \u2013 NASDAQ:MIRA", "summary": "This article focuses on the enterprise value to revenue forward metric for MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA). It appears to be a stub or data placeholder from TradingView, indicating that specific financial data for this metric is expected to be displayed. The content pro", "url": "https://www.tradingview.com/symbols/NASDAQ-MIRA/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T22:40:05", "published_display": "26 Jun 2026 22:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MIRA Pharmaceuticals, Inc. Actuals & Estimates (TRADEGATE:K6S)", "summary": "This article provides an overview of MIRA Pharmaceuticals, Inc. (TRADEGATE:K6S) including financial actuals and estimates. It details analyst forecasts for the stock, its historical highs and lows, upcoming earnings reports, recent net income, dividend policy (none), and employee", "url": "https://www.tradingview.com/symbols/TRADEGATE-K6S/forecast-actuals-and-estimates/?category=cash_flow", "source_name": "TradingView", "published_at": "2026-06-26T02:11:47", "published_display": "26 Jun 2026 02:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eli Lilly Stock - Analyst consensus stays bullish on weight-loss boom", "summary": "", "url": "https://news.google.com/rss/articles/CBMixAFBVV95cUxPMDk1SjNLOUw0ZDF6bHBsZ2c3TmlreVNCVnp3V3U2MDFobS1tMlhfS0JfcmJEWXlrQWZuNFRmbUF1bjQ2SUVlaTRYLW9FMnZrck9JQUY2dXBxbnZHbmMzV0ZjUVotbXNCTGJKazBSMzBWanRRbkdZSjdLTU04VWhvTF9wMWhBcHp0MlRUcGRNQlhMUzh4eFN6VVRTci1JSVpMMGdEanA4NmtCZW0wdGhGeE1iNnpvZ2lXZFpLa2x2amdNQWxR?oc=5", "source_name": "Ad Hoc News", "published_at": "2026-06-20T07:00:00+00:00", "published_display": "20 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Director receives 50,000 options at $0.94 at MIRA PHARMACEUTICALS, INC. (MIRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxORTg1dVdnZ1d2SjZoWFB6eEZDeGJJLWxyVmJYSnl4aWNFX3hTVllHVE8zbjFKWWNycXROZmJ2dXc3ZHZRMTVldFgxak5MbFdwR0xyazZ0bm1lckpDbWhOM3lnT1lKWjdVTThPeFJqeTNra2ZGcXBBaWQ1UmxFbDhhUUJyMDVmMmJkRl80dUNRR0ZRY1FXd2pobHVsYllteEtOZXdGWWNIcDlRVVhtRWhNNVR2QVpDWkFBbkE?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-15T07:00:00+00:00", "published_display": "15 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MIRA PHARMACEUTICALS (MIRA) director granted 50,000 stock options award", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxQaTVLWXdnZEhCSUFzMXVqWUN5QjREM3c5NEFXVzlOd2dFRjJNcUJxLUxKeW9rbFQtQWswd25oM08zTmZxemZLdjRFekhMRnZYRzhOUGdYRzRtVnc3S3pTNW1KZTYwYTdSelJhTnJ6YVA5eEt5OUFEY1VoYmVwZjVzcUpvbGtiQU9ncDJyVWdNV0pWVEwtMmE1RUpxQUpHVEoxT3FZRzVXblZLXzdjS0p5ZUYzUTY2ZmZFbFE?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-15T07:00:00+00:00", "published_display": "15 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MIRA Pharmaceuticals (MIRA) grants director 50,000 stock options at $0.94", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxQS3VyVk1HUTY1WkRuMTU0NnpOQVVYMkExenRXYlpMQ3Jvbl9zLUVzNEVfcll4a0U0UmJUV0JyUl96NXBCcjlpSWJ2SW4zNll2VTJSSVpZWENiNUxrYUx0VWxlbEVlTllPTHcxZ1IxdnZoM2lIR29vZU9iUlZ4ZVNhVkVhcFJrRGhfUFBMV3BYcHQ4Tkc2OUY4TWwtcGVrMklJRkVueDhLN2xFbkZjUU4wTFZDdGJ3bEl5Ync?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-15T07:00:00+00:00", "published_display": "15 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Sizzling 6.7% Dividend Yield? 1 Under-the-Radar Reason I Am Holding Off on Pfizer Stock at $25", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0wFBVV95cUxQSXJvRklCRkZvR2lkZGg0R2tXNzNkTGFRYVBHeEhVRWRSSnFmZDlPc20xUEhrVEU2OEFCYnVsVTJzMURvV2lJNnNOVU1QWEdocEdNUFBWTXJHcExUQUY2bzAzOHlHOXdrdDNBek14bGFFUTFJa2NVNExOSm5zV0xaeGJQNGhoUHN4X3QxTE5qeWhaeTV4ZWlETy03TXprRzY2Tm9POVlxU0VqUElDV0JGLWdPZUxiTzdkdmd5Z0w0bV9CTnIyLTlhMG94c3IweWI2NmJZ?oc=5", "source_name": "24/7 Wall St.", "published_at": "2026-06-11T07:00:00+00:00", "published_display": "11 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AMRN - Amarin Corp ADR Stock Price and Quote", "summary": "", "url": "https://news.google.com/rss/articles/CBMiRkFVX3lxTFBsZy1IWnNWaDhfUTZuaEZRcHVoWVd6SnlEYktFWC1ia2tlNGxhaE9qNVQ5ZFNxOWlqeDFuV0dsWUYzbkZpQ0E?oc=5", "source_name": "Finviz", "published_at": "2026-05-26T14:35:17+00:00", "published_display": "26 May 2026 14:35", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "UNH stock jumps on Q1 earnings beat and raised guidance to $18.25+", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxPTEprdzNMNGZxdkg5Wll5MTlvS1dheXQybm14TERTcGVzcHQzY0llOEpTa0dpZ1hGdHVyNWZ2cFFiWmZRdkl1aUp4YVlTMVJxSDRzaEdzRFB1cW93QzdhSmNxcEZDMWhGX2F0ODJFcjY1Mk1kMVhLNnVJSUhVMHZpRjRtTHo2cXBvbVJ3a05SWlJNMUdrSzFPbA?oc=5", "source_name": "eciks.org", "published_at": "2026-05-26T07:00:00+00:00", "published_display": "26 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 84, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mira Pharmaceuticals stock gains on Phase 1 trial results", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxQZWN4Z2hnaTMteFZhaGp0TXJyS1hXNXlyQ21CM3lQUERNNGVLTFBXaGQ5dk5tSXRXMGFHOUtra3hicUZOSlN3ZW9yWndIX21rX0hOaXFXN1pxNkZFRGEyb1ZYMFZvQVNBcUttYzJGNW1zbmhVemJKTXJWcDRnUHptRWZMUlZCajhnYzRabjhwT3FyQVNNMzF6aDdqUW5IVHR5ck4yUW54YTJPSmhqZnZzM2NaalFRb292RVpF?oc=5", "source_name": "Investing.com", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mira Murati's AI dream team got their stock options. Now many are out.", "summary": "", "url": "https://news.google.com/rss/articles/CBMikAFBVV95cUxPSzFONWs2d2RaMzhES0hSeW4yMEMySkNWMkw5WVZDWlpFaHdGUmM5U2VQLTFOclQzcVVvQmNZRlBFNGJBcDlwZlNRM21IS3VjMmJacG5HZXlUa2xIU0s4T2xQLXVrZWlQcVZzX1F6Qk5WRWh0UHlmaEN4bWliN3RPMGNRblRIc3dzSVdpTlpvMHo?oc=5", "source_name": "Business Insider", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GE HealthCare (NASDAQ:GEHC) Posts Better-Than-Expected Sales In Q1 CY2026 But Stock Drops", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3gFBVV95cUxOUjRRb0hlcHlOazlmelFaVVJSQWNnRmExZVBEQW1HMmVLTjNyU3d4WElsU05hdGlfYWFSY0twMTNWOVVCY0h4U2dYQ19BQl9pa3o0NWNBLW50WmFsSEVHdmJFV3JabnN5MFZpUWZabjZzY2tjMUtxbndONm9DS3NxTUp3Qjg2dWZnMDR2NXZ2eU80MWhSODVKdVgxZVJ6TWs3RFpCaDFqMXVtVkhmRVlOcWtqYUV1X1FPcGpfdERhRmwzdkZDaWxtSnJnd25Oam4yTnFHTFBkZi0tM1BZdkE?oc=5", "source_name": "StockStory", "published_at": "2026-04-29T07:00:00+00:00", "published_display": "29 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Abbott is the most oversold healthcare stock as Q1 earnings roll on (XLV:NYSEARCA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxOc2thQjFpazgwaFRfS3NjVXhlTkdFWHNFb240S0Z6akFtQXFIMmFmaXZnQ1A3OFVCQW9DT25OLVBQdGN5Yk52Mk9yUFlSX19ZS3FRTjZoR05zc2FVc25pVHQ0TDVHT2JmVnJabGNCREdLT2stV0IzLVdHWXpFZGU3V1NnVGhYbFRzNURVek41TVRmLWZQZTFYUkc4aXM0a1cwTkNFYTBfVnQ?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-04-22T07:00:00+00:00", "published_display": "22 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eli Lilly Stock Price (LLY) Holding On To $1000 Ahead of Earnings \u2013 What Next?", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxQMGFaM3RwNUQ1eXdUYi1sYVY1NWNTNkMyay01TlhDay1YZF8wQ2pmeGJGZmRGajdSekJYNnhGcHV2NW1QcWJpZG1zbjliMHpQTms0WmRSRnVXYVphZmJHZDVVXy1YV3VjeU82X3VUQXd2eDlJN1BEdURCZEhhR0V5Tl9BZUZ0QkdfLVFkN1hweEM5eGRpMU9IOHQ4UTUwS2hwM2VRclRzQ1hXaWdMSHc?oc=5", "source_name": "AskTraders", "published_at": "2026-02-04T08:00:00+00:00", "published_display": "04 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Merck Stock (MRK) Hitting Highs Into Earnings \u2013 Eyes On Breakout", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPU01ZWHVVLW9nUHQ3RDFuWmZrT3dmZ3VaNG1jWUNWanh6eGhlaWxmbkZ2X0JHX2NlZEg0ZEtsTHo4WTk0Ymc2Qm9CTml1U1dyNVdraFV5LXlPcGh1bDhZOFhILUZDdk9lVGNWdXpiY1FZODQtMFpGLTgzd2RFODlpRy1RU3FvdkJHWXVqRTRkUHo4NFNjVklSdnZ6dnNTUQ?oc=5", "source_name": "AskTraders", "published_at": "2026-02-03T08:00:00+00:00", "published_display": "03 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "UnitedHealth Stock Plummets 20% After Earnings. Why Soft Revenue Isn\u2019t the Only Problem.", "summary": "", "url": "https://news.google.com/rss/articles/CBMiggFBVV95cUxPMTdzUkZQWG9tTW9zT3FxSWtzdkdLLUNYVkRJMDh2X1VRSlVrdmVkS3FCSVFpX210VUxVSUF1Q2FYakw1ZUxyQlpoZHZpM1RYQzBOYlpEWENxeGM1bXBZNFYxQjZRcFBpcS0tVVhRdzFTejBrVzU3aU9QQXdnYkZBMWxB?oc=5", "source_name": "Barron's", "published_at": "2026-01-27T08:00:00+00:00", "published_display": "27 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MIRA Pharmaceuticals (MIRA) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiWkFVX3lxTE1wSzBnekVnZ0VLSFFlMS1jMlBmVGY0cndkczFabXp5UHJaSVVZQVp4c25sLU5fcXFueENrZ0ZDdGRORTR6Y05ITWg0dC1WUEFtUmVxZ29TQTJ3dw?oc=5", "source_name": "MarketBeat", "published_at": "2023-08-04T00:53:31+00:00", "published_display": "04 Aug 2023 00:53", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MIRA Stock Price and Chart \u2014 NASDAQ:MIRA", "summary": "", "url": "https://news.google.com/rss/articles/CBMiXEFVX3lxTFA1anlJZU5PUTlRYkVHbDBJcm94NWxhZkFPRFFuVXJkS0ZSVTZjRnBhamZUSkd3WENlZlVRajhLZXF2UFVOWTdteXZ4UjRhMFNubUhuaFFBdVFuOWU1?oc=5", "source_name": "TradingView", "published_at": "2023-08-03T18:51:22+00:00", "published_display": "03 Aug 2023 18:51", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "MIRA Pharmaceuticals (NASDAQ: MIRA) reports encouraging preclinical data for non-opioid pain candidate MIRA-55", "summary": "MIRA Pharmaceuticals announced positive preclinical results for MIRA-55, its non-opioid drug candidate for chronic inflammatory pain. The company selected an optimized oral formulation that showed favorable oral bioavailability, sustained systemic exposure, and reproducible distr", "url": "https://www.stocktitan.net/sec-filings/MIRA/8-k-mira-pharmaceuticals-inc-reports-material-event-bfdc4b7a0fdb.html", "source_name": "Stock Titan", "published_at": "2026-07-10T12:09:40", "published_display": "10 Jul 2026 12:09", "sentiment": "positive", "sentiment_pct": 70, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mira Pharmaceuticals Says SKNY-1 in Obesity, Addiction Shows 'Favorable' Bioavailability in Preclinical Studies", "summary": "Mira Pharmaceuticals (NASDAQ:MIRA) announced that its obesity and addiction drug candidate, SKNY-1, demonstrated favorable bioavailability and brain penetration in preclinical pharmacokinetic studies. These results support the drug's potential for once-daily oral dosing and its a", "url": "https://www.moomoo.com/news/post/72527367/mira-pharmaceuticals-says-skny-1-in-obesity-addiction-shows-favorable?futusource=news_newspage_recommend", "source_name": "Moomoo", "published_at": "2026-07-07T02:10:58", "published_display": "07 Jul 2026 02:10", "sentiment": "positive", "sentiment_pct": 74, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MIRA's obesity-and-addiction drug shows brain and liver exposure", "summary": "MIRA Pharmaceuticals (NASDAQ:MIRA) reported positive preclinical results for SKNY-1, an oral drug candidate for obesity and addiction. The optimized formulation demonstrated favorable oral bioavailability, reproducible systemic exposure, robust brain penetration, and substantial ", "url": "https://www.stocktitan.net/news/MIRA/mira-pharmaceuticals-reports-successful-formulation-results-for-skny-04tgs9z4po05.html", "source_name": "Stock Titan", "published_at": "2026-07-06T13:10:09", "published_display": "06 Jul 2026 13:10", "sentiment": "positive", "sentiment_pct": 93, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Japan firm's plant-based soup stock helps meet halal, vegan demand", "summary": "", "url": "https://news.google.com/rss/articles/CBMiygFBVV95cUxOY1M0RktyOUp6bnF4NmQxdEw3dkpYajV1c1RweG5DLXJWck9ZTUV1MGRNWXl3X2tFbHZsRG5xLXdoTUtZdnUwNVp3cWxLTXBCOWd4UHJSbGlhdkZjcFNZR3l0ZnFwSnFySHY0bWFrcnV1NkdBOXE1TzVxTk84cjNwZHJhcWk4WkZ0UVdkaERxbGxWZlluejE3cnVUaXRzdmY0b2NXaEhjZ19yaVMyM3RBclN1V1JSR19oMFpsYmVBb05ndlBGNHpNWC13?oc=5", "source_name": "The Star", "published_at": "2026-07-05T07:00:00+00:00", "published_display": "05 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "macro", "event_label": "Macro sensitivity", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MIRA Q3 2025 Earnings: Narrower Loss Reported, Stock Declines - EBITDA Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxQQWVKaWxBRXNabFRVWnNEZFFaNEhXZFNRaGI3M3JlLTV2Sk1EWHpuUE9FYWtiaUg3R2xGMmtQTWZST3duTG0yYk05Z3pZSHRIaFU4amgySXpteW1RdUdYcDBkVDlRNDZ3OUhYTC1OUDBQTjlQdUM4UTJlWmdZOG9xdGEzTnBKTEcyS1JxT0tCenFsNDY5bXdBVldLUEhFUmM2S2JHd1FZaXdjUQ?oc=5", "source_name": "Donan\u0131mHaber", "published_at": "2026-07-02T07:00:00+00:00", "published_display": "02 Jul 2026 07:00", "sentiment": "negative", "sentiment_pct": 18, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MIRA Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Whalen Matthew Pratt", "summary": "This document is a statement of changes in beneficial ownership of securities for Director Whalen Matthew Pratt at MIRA Pharmaceuticals. It is filed as a Form 4, indicating a mandatory disclosure for insiders regarding transactions in the company's stock.", "url": "https://www.moomoo.com/news/notice/307531901/mira-pharmaceuticals-4-statement-of-changes-in-beneficial-ownership-of", "source_name": "Moomoo", "published_at": "2026-06-30T16:41:12", "published_display": "30 Jun 2026 16:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MIRA Pharmaceuticals, Inc.(NasdaqCM: MIRA) added to Russell 3000E Growth Benchmark", "summary": "MIRA Pharmaceuticals, Inc. (NasdaqCM: MIRA) has been added to the Russell 3000E Growth Benchmark. This addition highlights the company's growth trajectory and its increasing recognition within the financial markets. MIRA Pharmaceuticals is a clinical-stage company focused on deve", "url": "https://www.marketscreener.com/news/mira-pharmaceuticals-inc-nasdaqcm-mira-added-to-russell-3000e-growth-benchmark-ce7f5fdedf8af223", "source_name": "www.marketscreener.com", "published_at": "2026-06-30T04:38:58", "published_display": "30 Jun 2026 04:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MIRA Pharmaceuticals, Inc.(NasdaqCM:MIRA) added to Russell Microcap Growth Benchmark Index", "summary": "MIRA Pharmaceuticals, Inc. (NasdaqCM:MIRA) has been added to the Russell Microcap Growth Benchmark Index. The company is a clinical-stage pharmaceutical firm focused on developing therapeutics for neurological, neuropsychiatric, and metabolic disorders. Its pipeline includes oral", "url": "https://www.marketscreener.com/news/mira-pharmaceuticals-inc-nasdaqcm-mira-added-to-russell-microcap-growth-benchmark-index-ce7f5fded08df720", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T12:12:16", "published_display": "29 Jun 2026 12:12", "sentiment": "positive", "sentiment_pct": 95, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MIRA Pharmaceuticals, Inc.(NasdaqCM: MIRA) added to Russell 3000E Index", "summary": "MIRA Pharmaceuticals (NasdaqCM: MIRA), a clinical-stage pharmaceutical company, has been added to the Russell 3000E Index. The company focuses on developing therapeutics for neurologic, neuropsychiatric, and metabolic disorders, with a pipeline that includes drug candidates for n", "url": "https://www.marketscreener.com/news/mira-pharmaceuticals-inc-nasdaqcm-mira-added-to-russell-3000e-index-ce7f5fdcdd89fe25", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T03:09:57", "published_display": "29 Jun 2026 03:09", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of MIRA Pharmaceuticals, Inc. \u2013 NASDAQ:MIRA", "summary": "This article provides financial information for MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA), specifically focusing on its forward price-to-sales ratio. It appears to be a stub or a section from a larger financial data platform, indicating the company's status on the Nasdaq Stock Ma", "url": "https://www.tradingview.com/symbols/NASDAQ-MIRA/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T04:38:58", "published_display": "28 Jun 2026 04:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of MIRA Pharmaceuticals, Inc. \u2013 NASDAQ:MIRA", "summary": "This article provides financial information for MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) focusing on its price-to-earnings forward metric. It details the company's presence on the Nasdaq Stock Market and references data from ICE Data Services, FactSet, and Quartr for financial r", "url": "https://www.tradingview.com/symbols/NASDAQ-MIRA/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T04:08:53", "published_display": "27 Jun 2026 04:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MIRA Pharmaceuticals, Inc. Actuals & Estimates (FWB:K6S)", "summary": "This article provides an overview of MIRA Pharmaceuticals, Inc. (FWB:K6S), including financial actuals and estimates, stock forecasts, and company information. According to analysts, the stock has a maximum estimate of 8.18 EUR and a minimum estimate of 8.18 EUR, with the next ea", "url": "https://www.tradingview.com/symbols/FWB-K6S/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-27T02:40:21", "published_display": "27 Jun 2026 02:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MIRA Pharmaceuticals, Inc. Actuals & Estimates (MUN:K6S)", "summary": "This article provides an overview of MIRA Pharmaceuticals, Inc. (K6S) stock performance and financial data on the Munich Stock Exchange. It includes analyst forecasts, historical price data, upcoming earnings report dates, and key financial figures such as net income and employee", "url": "https://www.tradingview.com/symbols/MUN-K6S/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-27T01:39:32", "published_display": "27 Jun 2026 01:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of MIRA Pharmaceuticals, Inc. \u2013 NASDAQ:MIRA", "summary": "This article focuses on the enterprise value to revenue forward metric for MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA). It appears to be a stub or data placeholder from TradingView, indicating that specific financial data for this metric is expected to be displayed. The content pro", "url": "https://www.tradingview.com/symbols/NASDAQ-MIRA/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T22:40:05", "published_display": "26 Jun 2026 22:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MIRA Pharmaceuticals, Inc. Actuals & Estimates (TRADEGATE:K6S)", "summary": "This article provides an overview of MIRA Pharmaceuticals, Inc. (TRADEGATE:K6S) including financial actuals and estimates. It details analyst forecasts for the stock, its historical highs and lows, upcoming earnings reports, recent net income, dividend policy (none), and employee", "url": "https://www.tradingview.com/symbols/TRADEGATE-K6S/forecast-actuals-and-estimates/?category=cash_flow", "source_name": "TradingView", "published_at": "2026-06-26T02:11:47", "published_display": "26 Jun 2026 02:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eli Lilly Stock - Analyst consensus stays bullish on weight-loss boom", "summary": "", "url": "https://news.google.com/rss/articles/CBMixAFBVV95cUxPMDk1SjNLOUw0ZDF6bHBsZ2c3TmlreVNCVnp3V3U2MDFobS1tMlhfS0JfcmJEWXlrQWZuNFRmbUF1bjQ2SUVlaTRYLW9FMnZrck9JQUY2dXBxbnZHbmMzV0ZjUVotbXNCTGJKazBSMzBWanRRbkdZSjdLTU04VWhvTF9wMWhBcHp0MlRUcGRNQlhMUzh4eFN6VVRTci1JSVpMMGdEanA4NmtCZW0wdGhGeE1iNnpvZ2lXZFpLa2x2amdNQWxR?oc=5", "source_name": "Ad Hoc News", "published_at": "2026-06-20T07:00:00+00:00", "published_display": "20 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Director receives 50,000 options at $0.94 at MIRA PHARMACEUTICALS, INC. (MIRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxORTg1dVdnZ1d2SjZoWFB6eEZDeGJJLWxyVmJYSnl4aWNFX3hTVllHVE8zbjFKWWNycXROZmJ2dXc3ZHZRMTVldFgxak5MbFdwR0xyazZ0bm1lckpDbWhOM3lnT1lKWjdVTThPeFJqeTNra2ZGcXBBaWQ1UmxFbDhhUUJyMDVmMmJkRl80dUNRR0ZRY1FXd2pobHVsYllteEtOZXdGWWNIcDlRVVhtRWhNNVR2QVpDWkFBbkE?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-15T07:00:00+00:00", "published_display": "15 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MIRA PHARMACEUTICALS (MIRA) director granted 50,000 stock options award", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxQaTVLWXdnZEhCSUFzMXVqWUN5QjREM3c5NEFXVzlOd2dFRjJNcUJxLUxKeW9rbFQtQWswd25oM08zTmZxemZLdjRFekhMRnZYRzhOUGdYRzRtVnc3S3pTNW1KZTYwYTdSelJhTnJ6YVA5eEt5OUFEY1VoYmVwZjVzcUpvbGtiQU9ncDJyVWdNV0pWVEwtMmE1RUpxQUpHVEoxT3FZRzVXblZLXzdjS0p5ZUYzUTY2ZmZFbFE?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-15T07:00:00+00:00", "published_display": "15 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MIRA Pharmaceuticals (MIRA) grants director 50,000 stock options at $0.94", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxQS3VyVk1HUTY1WkRuMTU0NnpOQVVYMkExenRXYlpMQ3Jvbl9zLUVzNEVfcll4a0U0UmJUV0JyUl96NXBCcjlpSWJ2SW4zNll2VTJSSVpZWENiNUxrYUx0VWxlbEVlTllPTHcxZ1IxdnZoM2lIR29vZU9iUlZ4ZVNhVkVhcFJrRGhfUFBMV3BYcHQ4Tkc2OUY4TWwtcGVrMklJRkVueDhLN2xFbkZjUU4wTFZDdGJ3bEl5Ync?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-15T07:00:00+00:00", "published_display": "15 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Sizzling 6.7% Dividend Yield? 1 Under-the-Radar Reason I Am Holding Off on Pfizer Stock at $25", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0wFBVV95cUxQSXJvRklCRkZvR2lkZGg0R2tXNzNkTGFRYVBHeEhVRWRSSnFmZDlPc20xUEhrVEU2OEFCYnVsVTJzMURvV2lJNnNOVU1QWEdocEdNUFBWTXJHcExUQUY2bzAzOHlHOXdrdDNBek14bGFFUTFJa2NVNExOSm5zV0xaeGJQNGhoUHN4X3QxTE5qeWhaeTV4ZWlETy03TXprRzY2Tm9POVlxU0VqUElDV0JGLWdPZUxiTzdkdmd5Z0w0bV9CTnIyLTlhMG94c3IweWI2NmJZ?oc=5", "source_name": "24/7 Wall St.", "published_at": "2026-06-11T07:00:00+00:00", "published_display": "11 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AMRN - Amarin Corp ADR Stock Price and Quote", "summary": "", "url": "https://news.google.com/rss/articles/CBMiRkFVX3lxTFBsZy1IWnNWaDhfUTZuaEZRcHVoWVd6SnlEYktFWC1ia2tlNGxhaE9qNVQ5ZFNxOWlqeDFuV0dsWUYzbkZpQ0E?oc=5", "source_name": "Finviz", "published_at": "2026-05-26T14:35:17+00:00", "published_display": "26 May 2026 14:35", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "UNH stock jumps on Q1 earnings beat and raised guidance to $18.25+", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxPTEprdzNMNGZxdkg5Wll5MTlvS1dheXQybm14TERTcGVzcHQzY0llOEpTa0dpZ1hGdHVyNWZ2cFFiWmZRdkl1aUp4YVlTMVJxSDRzaEdzRFB1cW93QzdhSmNxcEZDMWhGX2F0ODJFcjY1Mk1kMVhLNnVJSUhVMHZpRjRtTHo2cXBvbVJ3a05SWlJNMUdrSzFPbA?oc=5", "source_name": "eciks.org", "published_at": "2026-05-26T07:00:00+00:00", "published_display": "26 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 84, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mira Pharmaceuticals stock gains on Phase 1 trial results", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxQZWN4Z2hnaTMteFZhaGp0TXJyS1hXNXlyQ21CM3lQUERNNGVLTFBXaGQ5dk5tSXRXMGFHOUtra3hicUZOSlN3ZW9yWndIX21rX0hOaXFXN1pxNkZFRGEyb1ZYMFZvQVNBcUttYzJGNW1zbmhVemJKTXJWcDRnUHptRWZMUlZCajhnYzRabjhwT3FyQVNNMzF6aDdqUW5IVHR5ck4yUW54YTJPSmhqZnZzM2NaalFRb292RVpF?oc=5", "source_name": "Investing.com", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mira Murati's AI dream team got their stock options. Now many are out.", "summary": "", "url": "https://news.google.com/rss/articles/CBMikAFBVV95cUxPSzFONWs2d2RaMzhES0hSeW4yMEMySkNWMkw5WVZDWlpFaHdGUmM5U2VQLTFOclQzcVVvQmNZRlBFNGJBcDlwZlNRM21IS3VjMmJacG5HZXlUa2xIU0s4T2xQLXVrZWlQcVZzX1F6Qk5WRWh0UHlmaEN4bWliN3RPMGNRblRIc3dzSVdpTlpvMHo?oc=5", "source_name": "Business Insider", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GE HealthCare (NASDAQ:GEHC) Posts Better-Than-Expected Sales In Q1 CY2026 But Stock Drops", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3gFBVV95cUxOUjRRb0hlcHlOazlmelFaVVJSQWNnRmExZVBEQW1HMmVLTjNyU3d4WElsU05hdGlfYWFSY0twMTNWOVVCY0h4U2dYQ19BQl9pa3o0NWNBLW50WmFsSEVHdmJFV3JabnN5MFZpUWZabjZzY2tjMUtxbndONm9DS3NxTUp3Qjg2dWZnMDR2NXZ2eU80MWhSODVKdVgxZVJ6TWs3RFpCaDFqMXVtVkhmRVlOcWtqYUV1X1FPcGpfdERhRmwzdkZDaWxtSnJnd25Oam4yTnFHTFBkZi0tM1BZdkE?oc=5", "source_name": "StockStory", "published_at": "2026-04-29T07:00:00+00:00", "published_display": "29 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Abbott is the most oversold healthcare stock as Q1 earnings roll on (XLV:NYSEARCA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxOc2thQjFpazgwaFRfS3NjVXhlTkdFWHNFb240S0Z6akFtQXFIMmFmaXZnQ1A3OFVCQW9DT25OLVBQdGN5Yk52Mk9yUFlSX19ZS3FRTjZoR05zc2FVc25pVHQ0TDVHT2JmVnJabGNCREdLT2stV0IzLVdHWXpFZGU3V1NnVGhYbFRzNURVek41TVRmLWZQZTFYUkc4aXM0a1cwTkNFYTBfVnQ?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-04-22T07:00:00+00:00", "published_display": "22 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eli Lilly Stock Price (LLY) Holding On To $1000 Ahead of Earnings \u2013 What Next?", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxQMGFaM3RwNUQ1eXdUYi1sYVY1NWNTNkMyay01TlhDay1YZF8wQ2pmeGJGZmRGajdSekJYNnhGcHV2NW1QcWJpZG1zbjliMHpQTms0WmRSRnVXYVphZmJHZDVVXy1YV3VjeU82X3VUQXd2eDlJN1BEdURCZEhhR0V5Tl9BZUZ0QkdfLVFkN1hweEM5eGRpMU9IOHQ4UTUwS2hwM2VRclRzQ1hXaWdMSHc?oc=5", "source_name": "AskTraders", "published_at": "2026-02-04T08:00:00+00:00", "published_display": "04 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Merck Stock (MRK) Hitting Highs Into Earnings \u2013 Eyes On Breakout", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPU01ZWHVVLW9nUHQ3RDFuWmZrT3dmZ3VaNG1jWUNWanh6eGhlaWxmbkZ2X0JHX2NlZEg0ZEtsTHo4WTk0Ymc2Qm9CTml1U1dyNVdraFV5LXlPcGh1bDhZOFhILUZDdk9lVGNWdXpiY1FZODQtMFpGLTgzd2RFODlpRy1RU3FvdkJHWXVqRTRkUHo4NFNjVklSdnZ6dnNTUQ?oc=5", "source_name": "AskTraders", "published_at": "2026-02-03T08:00:00+00:00", "published_display": "03 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "UnitedHealth Stock Plummets 20% After Earnings. Why Soft Revenue Isn\u2019t the Only Problem.", "summary": "", "url": "https://news.google.com/rss/articles/CBMiggFBVV95cUxPMTdzUkZQWG9tTW9zT3FxSWtzdkdLLUNYVkRJMDh2X1VRSlVrdmVkS3FCSVFpX210VUxVSUF1Q2FYakw1ZUxyQlpoZHZpM1RYQzBOYlpEWENxeGM1bXBZNFYxQjZRcFBpcS0tVVhRdzFTejBrVzU3aU9QQXdnYkZBMWxB?oc=5", "source_name": "Barron's", "published_at": "2026-01-27T08:00:00+00:00", "published_display": "27 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MIRA Pharmaceuticals (MIRA) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiWkFVX3lxTE1wSzBnekVnZ0VLSFFlMS1jMlBmVGY0cndkczFabXp5UHJaSVVZQVp4c25sLU5fcXFueENrZ0ZDdGRORTR6Y05ITWg0dC1WUEFtUmVxZ29TQTJ3dw?oc=5", "source_name": "MarketBeat", "published_at": "2023-08-04T00:53:31+00:00", "published_display": "04 Aug 2023 00:53", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MIRA Stock Price and Chart \u2014 NASDAQ:MIRA", "summary": "", "url": "https://news.google.com/rss/articles/CBMiXEFVX3lxTFA1anlJZU5PUTlRYkVHbDBJcm94NWxhZkFPRFFuVXJkS0ZSVTZjRnBhamZUSkd3WENlZlVRajhLZXF2UFVOWTdteXZ4UjRhMFNubUhuaFFBdVFuOWU1?oc=5", "source_name": "TradingView", "published_at": "2023-08-03T18:51:22+00:00", "published_display": "03 Aug 2023 18:51", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [], "sector": []}, "total_fetched": 85, "total_relevant": 31, "sentiment_summary": {"positive": 8, "negative": 1, "neutral": 22, "score": 57, "total": 31, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "earnings", "primary_label": "Earnings", "confidence": 77, "events": [{"event": "earnings", "label": "Earnings", "weight": 8.4, "count": 14}, {"event": "general", "label": "Market update", "weight": 7.7, "count": 14}, {"event": "macro", "label": "Macro sensitivity", "weight": 0.55, "count": 1}, {"event": "analyst", "label": "Analyst action", "weight": 0.55, "count": 1}, {"event": "capital_return", "label": "Capital return", "weight": 0.55, "count": 1}], "positive_events": 8, "negative_events": 1}, "market_context": {"has_market_context": true, "latest_close": 0.92, "latest_week": "2026-07-10", "one_week_move": -2.1, "four_week_move": -1.6, "twelve_week_move": -12.8, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": -0.178744, "market_dynamics_buy_signal": false, "relative_strength": -38.865707, "fair_value_gap": -41.1, "fair_value_label": "Below fair value", "fair_value_tone": "positive", "expectation_direction": "undecided", "expectation_probability": 49.2184, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-2.1% over one week, -1.6% over four weeks, trend inactive, and below fair value."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 65, "badges": ["Value support"], "opportunities": ["Price is below fair value while news tone is not negative."], "risks": [], "event_label": "Earnings", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "TradingView", "count": 7}, {"label": "Stock Titan", "count": 5}, {"label": "www.marketscreener.com", "count": 3}, {"label": "Moomoo", "count": 2}, {"label": "AskTraders", "count": 2}, {"label": "The Star", "count": 1}, {"label": "Donan\u0131mHaber", "count": 1}, {"label": "Ad Hoc News", "count": 1}], "tiers": [{"label": "Direct company coverage", "count": 31}, {"label": "Industry context", "count": 0}, {"label": "Sector context", "count": 0}], "events": [{"label": "Earnings", "count": 14}, {"label": "Market update", "count": 14}, {"label": "Macro sensitivity", "count": 1}, {"label": "Analyst action", "count": 1}, {"label": "Capital return", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "57/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Earnings", "tone": "neutral", "text": "77/100 classification confidence."}, {"label": "Company focus", "value": "31", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "2", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "-2.1% over one week, -1.6% over four weeks, trend inactive, and below fair value."}, {"label": "Latest direct headline", "value": "Positive", "tone": "positive", "text": "MIRA Pharmaceuticals (NASDAQ: MIRA) reports encouraging preclinical data for non-opioid pain candidate MIRA-55"}], "updated_at": "2026-07-16T07:05:03.475777+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}